{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062017","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.481629+00:00","generated_at":"2026-06-08T06:07:56.452472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MEI Pharma Q1 net income $56.4M on deferred revenue; clinical trials on track","bullets":["Net income $56.4M ($8.46 EPS) vs prior-year net loss $16.6M; revenue $65.3M from Kyowa Kirin termination.","Cash $82.2M with no debt; operating cash burn $18.5M; funds operations for at least 12 months through data readouts.","Voruciclib (CDK9) Phase 1 combo with venetoclax dose-escalation data expected early 2024.","ME-344 (mitochondrial inhibitor) Phase 1b combo with bevacizumab first-cohort data expected H1 2024.","Abstract on voruciclib monotherapy dose escalation to be presented at ASH Dec 9-12, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062017","json":"https://secwatch.observer/filing/0000950170-23-062017.json","markdown":"https://secwatch.observer/filing/0000950170-23-062017.md","text":"https://secwatch.observer/filing/0000950170-23-062017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023062017/0000950170-23-062017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023062017/meip-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:07:56.452472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d33cc48cc7d779730459f0e58a53dfad4744077","claim":"Lite Strategy, Inc. reported first quarter ended September 30, 2023 results: revenue $65.3 million, net income $56.4 million, EPS $8.46 per share.","evidence_excerpt":"and related costs from our fiscal year 2023 reduction in headcount, partially offset by higher external professional services and legal expenses. • MEI recognized revenue of $65.3 million for the quarter ended September 30, 2023, compared to $8.7 million for the quarter ended September 30, 2022. The increase in revenue is due to the recognition of deferred revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000095017023062017/0000950170-23-062017-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended September 30, 2023"},{"label":"Revenue","value":"$65.3 million"},{"label":"Net income","value":"$56.4 million"},{"label":"EPS","value":"$8.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}